ID: ALA5195225

Max Phase: Preclinical

Molecular Formula: C21H17N3O3S

Molecular Weight: 391.45

Representations

Canonical SMILES:  CCOC(=O)C1=C(Nc2ccccc2)S/C(=C\c2cc3ncccc3[nH]2)C1=O

Standard InChI:  InChI=1S/C21H17N3O3S/c1-2-27-21(26)18-19(25)17(28-20(18)24-13-7-4-3-5-8-13)12-14-11-16-15(23-14)9-6-10-22-16/h3-12,23-24H,2H2,1H3/b17-12-

Standard InChI Key:  BXSRZRACIZHJET-ATVHPVEESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 391.45

Molecular Weight (Monoisotopic): 391.0991

AlogP: 4.11

#Rotatable Bonds: 5

Polar Surface Area: 84.08

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.04

CX Basic pKa: 4.43

CX LogP: 3.91

CX LogD: 3.91

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.39

Np Likeness Score: -1.13

References

1. Hwang J, Qiu X, Borgelt L, Haacke N, Kanis L, Petroulia S, Gasper R, Schiller D, Lampe P, Sievers S, Imig J, Wu P..  (2022)  Synthesis and evaluation of RNase L-binding 2-aminothiophenes as anticancer agents.,  58  [PMID:35152173] [10.1016/j.bmc.2022.116653]

2. Duvauchelle V, Meffre P, Benfodda Z..  (2022)  Recent contribution of medicinally active 2-aminothiophenes: A privileged scaffold for drug discovery.,  238  [PMID:35696863] [10.1016/j.ejmech.2022.114502]

Source

Source(1):

• Scientific Literature